On October 4, 2024, District Judge Philip M. Halpern (S.D.N.Y.) denied Defendant Regeneron Pharmaceuticals Inc. (“Regeneron”)’s Motion for Summary Judgment that (1) Allele was not entitled to any pre-suit infringement damages because it did not properly mark; and (2) that Regeneron did not willfully infringe the ’211 patent. Slip Op. at 1-2. The Court also granted Plaintiff Allele Biotechnology & Pharmaceuticals, Inc. (“Allele”)’s Motion for Summary Judgment that the 35 U.S.C. § 271(e)(1) safe…
By: Patterson Belknap Webb & Tyler LLP
By: Patterson Belknap Webb & Tyler LLP